See the DrugPatentWatch profile for Abilify
Abilify Maintena is an antipsychotic medication used to treat schizophrenia and bipolar I disorder. Its price can vary significantly depending on factors such as dosage, quantity purchased, insurance coverage, and pharmacy. As a prescription drug, a direct cash price is not uniformly set.
What factors influence Abilify Maintena's price?
The cost of Abilify Maintena is influenced by several elements. These include the specific dosage prescribed, as higher strengths may cost more. The quantity of medication dispensed also plays a role, with larger supplies potentially offering a lower per-unit cost. Insurance plans have a substantial impact, as co-pays and deductibles vary widely. Without insurance, the out-of-pocket expense for Abilify Maintena can be considerable. Patient assistance programs offered by the manufacturer or third parties may also be available to help reduce costs for eligible individuals.
How does Abilify Maintena compare to other long-acting antipsychotics?
Abilify Maintena is a long-acting injectable (LAI) antipsychotic, meaning it is administered by a healthcare professional at intervals, typically monthly. Other LAIs include medications like haloperidol decanoate, fluphenazine decanoate, risperidone consta, paliperidone palmitate (Invega Sustenna/Trinza), aripiprazole lauroxil (Aristada), and olanzapine pamoate (Zyprexa Relprevv). The choice among these often depends on individual patient response, tolerability, administration frequency, and cost. Prices can differ across these LAIs, and their effectiveness and side effect profiles also vary, influencing which medication is chosen for a patient.
When does Abilify Maintena's patent expire?
The patent landscape for Abilify Maintena is complex and involves multiple patents covering the drug itself, its formulation, and its method of use. The original patents for aripiprazole, the active ingredient in Abilify Maintena, have expired, allowing for generic versions of the oral tablet. However, patents specific to the long-acting injectable formulation of Abilify Maintena may have different expiration dates. Information regarding specific patent expiration dates for Abilify Maintena can be found on resources like DrugPatentWatch.com [1].
Can generic versions of Abilify Maintena become available?
The availability of generic versions of Abilify Maintena depends on the expiration of patents covering its specific long-acting injectable formulation. Even after core patents expire, other patents related to manufacturing processes or specific delivery mechanisms can sometimes delay the introduction of generics. The development and approval of generic LAIs are also complex processes, and their market entry can differ significantly from oral medications.
What are the risks and side effects associated with Abilify Maintena?
Like all medications, Abilify Maintena carries potential risks and side effects. Common side effects can include injection site reactions, weight gain, drowsiness, movement disorders (such as akathisia, parkinsonism, and tardive dyskinesia), and increased cholesterol levels. More serious, though less common, side effects can include neuroleptic malignant syndrome, a potentially fatal condition, and metabolic changes that increase the risk of diabetes and high blood sugar. Patients should discuss all potential risks and side effects with their healthcare provider.
How is Abilify Maintena administered?
Abilify Maintena is administered as an intramuscular injection. It is typically given by a healthcare professional, such as a doctor, nurse, or pharmacist, in a clinic or doctor's office. The injection is usually given once a month. The specific site and technique of injection are important to ensure proper delivery and absorption of the medication.
Are there patient assistance programs for Abilify Maintena?
Yes, manufacturers of Abilify Maintena, like other pharmaceutical companies, often provide patient assistance programs. These programs aim to help individuals who have financial difficulties in affording their medication. Eligibility for these programs usually depends on income, insurance status, and other criteria. Information on how to access these programs is typically available through the drug's manufacturer or a healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/